Lv5
930 积分 2024-09-30 加入
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
9天前
已完结
47P First-line pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC) in the China subpopulation from the phase III KEYNOTE-966 study
9天前
已关闭
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
9天前
已完结
Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study
11天前
已完结
Atezolizumab and Bevacizumab with Transarterial Chemoembolization in Hepatocellular Carcinoma: The DEMAND Trial Protocol
14天前
已完结
我国三级公立医院出院患者随访工作现状调查
17天前
已完结
我国三级肿瘤医院多学科诊疗模式开展现状调查
17天前
已完结
胆道恶性肿瘤精准靶向治疗的研究进展
22天前
已完结
Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study
23天前
已完结
Complete Response to Immunotherapy in Patients With Hepatocellular Carcinoma
1个月前
已关闭
皖公网安备34019202002308
